CME Group Inc. director Robert J. Tierney Jr. reported a change in his beneficial ownership of CME Class A common stock tied to the company’s director compensation program. The reported transaction occurred on June 25, 2026, and involved a grant of CME Group Class A common stock to Tierney. According to the explanatory note in the filing, the shares were issued as part of CME Group’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. The filing states that the shares were “fully vested” at the time of grant and are not subject to any vesting conditions. That means Tierney received unrestricted ownership of the shares immediately, rather than receiving stock that would vest over time or upon continued service. The provided filing text does not disclose the number of shares granted, the transaction price, the transaction code, or Tierney’s beneficial ownership total after the transaction. The report was signed on June 29, 2026, by Elizabeth Hensen as attorney-in-fact for Robert J. Tierney Jr. The action is routine for public-company directors: annual stock grants are commonly used to align non-employee directors’ interests with shareholders by compensating them partly in company equity.